Option chain shows key data for Moleculin Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Moleculin Biotech.

Moleculin Biotech (NASDAQ:MBRX) Stock, Option Chain

Moleculin Biotech

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

nyse shutter

Analyst Color

Asia

Earnings

Earnings Beats

Earnings Misses

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

News

Regulations

Bonds

Broad U.S. Equity ETFs

Emerging Markets

Eurozone

Futures

Commodities

Forex

Economics

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

General

ABNB

BLAC

ESNT

MBRX

MRNA

MYNA

NVDA

TSLA

U.S. stock futures traded close to the flatline on Friday after Tuesday&#39;s rally. Futures of all four benchmark indices were slightly lower.

US Stocks Set For A Volatile Start: Analyst Dismisses Chances Of 20%+ S&amp;P 500 Gain For Third Year In A Row, But Says &#39;Investors Should Be Optimistic&#39;

airbnb shutter

BSLK

CNSP

FFIE

INFA

JRSH

PCLA

SLSR

STAI

STVN

VRPX

ZCAR

Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

Movers

Trading Ideas

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026.

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Biotech Inc

Press Releases

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

Small Cap

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Participates in Virtual Investor "What This Means" Segment

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Offerings

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

"Signal Advance, Inc. (OTC: SIGL) Achieves Technology Milestone with Revolutionary Next-Gen Signal Protection – More Stocks Inside"

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Comments

Moleculin Biotech

Moleculin Biotech (MBRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga